These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 39171753)

  • 1. Small molecule inhibition of glycogen synthase I reduces muscle glycogen content and improves biomarkers in a mouse model of Pompe disease.
    Gaspar RC; Sakuma I; Nasiri A; Hubbard BT; LaMoia TE; Leitner BP; Tep S; Xi Y; Green EM; Ullman JC; Petersen KF; Shulman GI
    Am J Physiol Endocrinol Metab; 2024 Oct; 327(4):E524-E532. PubMed ID: 39171753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restoration of muscle functionality by genetic suppression of glycogen synthesis in a murine model of Pompe disease.
    Douillard-Guilloux G; Raben N; Takikita S; Ferry A; Vignaud A; Guillet-Deniau I; Favier M; Thurberg BL; Roach PJ; Caillaud C; Richard E
    Hum Mol Genet; 2010 Feb; 19(4):684-96. PubMed ID: 19959526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small-molecule inhibition of glycogen synthase 1 for the treatment of Pompe disease and other glycogen storage disorders.
    Ullman JC; Mellem KT; Xi Y; Ramanan V; Merritt H; Choy R; Gujral T; Young LEA; Blake K; Tep S; Homburger JR; O'Regan A; Ganesh S; Wong P; Satterfield TF; Lin B; Situ E; Yu C; Espanol B; Sarwaikar R; Fastman N; Tzitzilonis C; Lee P; Reiton D; Morton V; Santiago P; Won W; Powers H; Cummings BB; Hoek M; Graham RR; Chandriani SJ; Bainer R; DePaoli-Roach AA; Roach PJ; Hurley TD; Sun RC; Gentry MS; Sinz C; Dick RA; Noonberg SB; Beattie DT; Morgans DJ; Green EM
    Sci Transl Med; 2024 Jan; 16(730):eadf1691. PubMed ID: 38232139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dysregulation of multiple facets of glycogen metabolism in a murine model of Pompe disease.
    Taylor KM; Meyers E; Phipps M; Kishnani PS; Cheng SH; Scheule RK; Moreland RJ
    PLoS One; 2013; 8(2):e56181. PubMed ID: 23457523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic Delivery of AAVB1-GAA Clears Glycogen and Prolongs Survival in a Mouse Model of Pompe Disease.
    Keeler AM; Zieger M; Todeasa SH; McCall AL; Gifford JC; Birsak S; Choudhury SR; Byrne BJ; Sena-Esteves M; ElMallah MK
    Hum Gene Ther; 2019 Jan; 30(1):57-68. PubMed ID: 29901418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjunctive β2-agonist treatment reduces glycogen independently of receptor-mediated acid α-glucosidase uptake in the limb muscles of mice with Pompe disease.
    Farah BL; Madden L; Li S; Nance S; Bird A; Bursac N; Yen PM; Young SP; Koeberl DD
    FASEB J; 2014 May; 28(5):2272-80. PubMed ID: 24448824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody formation and mannose-6-phosphate receptor expression impact the efficacy of muscle-specific transgene expression in murine Pompe disease.
    Sun B; Li S; Bird A; Yi H; Kemper A; Thurberg BL; Koeberl DD
    J Gene Med; 2010 Nov; 12(11):881-91. PubMed ID: 20967919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene therapy with secreted acid alpha-glucosidase rescues Pompe disease in a novel mouse model with early-onset spinal cord and respiratory defects.
    Colella P; Sellier P; Gomez MJ; Biferi MG; Tanniou G; Guerchet N; Cohen-Tannoudji M; Moya-Nilges M; van Wittenberghe L; Daniele N; Gjata B; Krijnse-Locker J; Collaud F; Simon-Sola M; Charles S; Cagin U; Mingozzi F
    EBioMedicine; 2020 Nov; 61():103052. PubMed ID: 33039711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rescue of Advanced Pompe Disease in Mice with Hepatic Expression of Secretable Acid α-Glucosidase.
    Cagin U; Puzzo F; Gomez MJ; Moya-Nilges M; Sellier P; Abad C; Van Wittenberghe L; Daniele N; Guerchet N; Gjata B; Collaud F; Charles S; Sola MS; Boyer O; Krijnse-Locker J; Ronzitti G; Colella P; Mingozzi F
    Mol Ther; 2020 Sep; 28(9):2056-2072. PubMed ID: 32526204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacological chaperone AT2220 increases the specific activity and lysosomal delivery of mutant acid alpha-glucosidase, and promotes glycogen reduction in a transgenic mouse model of Pompe disease.
    Khanna R; Powe AC; Lun Y; Soska R; Feng J; Dhulipala R; Frascella M; Garcia A; Pellegrino LJ; Xu S; Brignol N; Toth MJ; Do HV; Lockhart DJ; Wustman BA; Valenzano KJ
    PLoS One; 2014; 9(7):e102092. PubMed ID: 25036864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reveglucosidase alfa (BMN 701), an IGF2-Tagged rhAcid α-Glucosidase, Improves Respiratory Functional Parameters in a Murine Model of Pompe Disease.
    Peng J; Dalton J; Butt M; Tracy K; Kennedy D; Haroldsen P; Cahayag R; Zoog S; O'Neill CA; Tsuruda LS
    J Pharmacol Exp Ther; 2017 Feb; 360(2):313-323. PubMed ID: 27856936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Airway smooth muscle dysfunction in Pompe (
    Keeler AM; Liu D; Zieger M; Xiong L; Salemi J; Bellvé K; Byrne BJ; Fuller DD; ZhuGe R; ElMallah MK
    Am J Physiol Lung Cell Mol Physiol; 2017 Jun; 312(6):L873-L881. PubMed ID: 28336814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-dimensional tissue-engineered human skeletal muscle model of Pompe disease.
    Wang J; Zhou CJ; Khodabukus A; Tran S; Han SO; Carlson AL; Madden L; Kishnani PS; Koeberl DD; Bursac N
    Commun Biol; 2021 May; 4(1):524. PubMed ID: 33953320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GAA deficiency disrupts distal airway cells in Pompe disease.
    El Haddad L; Lai E; Murthy PKL; Biswas DD; Soufny R; Roger AL; Tata PR; ElMallah MK
    Am J Physiol Lung Cell Mol Physiol; 2023 Sep; 325(3):L288-L298. PubMed ID: 37366541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle.
    Koeberl DD; Luo X; Sun B; McVie-Wylie A; Dai J; Li S; Banugaria SG; Chen YT; Bali DS
    Mol Genet Metab; 2011 Jun; 103(2):107-12. PubMed ID: 21397538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lysosomal glycogen accumulation in Pompe disease results in disturbed cytoplasmic glycogen metabolism.
    Canibano-Fraile R; Harlaar L; Dos Santos CA; Hoogeveen-Westerveld M; Demmers JAA; Snijders T; Lijnzaad P; Verdijk RM; van der Beek NAME; van Doorn PA; van der Ploeg AT; Brusse E; Pijnappel WWMP; Schaaf GJ
    J Inherit Metab Dis; 2023 Jan; 46(1):101-115. PubMed ID: 36111639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyaluronidase increases the biodistribution of acid alpha-1,4 glucosidase in the muscle of Pompe disease mice: an approach to enhance the efficacy of enzyme replacement therapy.
    Matalon R; Surendran S; Campbell GA; Michals-Matalon K; Tyring SK; Grady J; Cheng S; Kaye E
    Biochem Biophys Res Commun; 2006 Nov; 350(3):783-7. PubMed ID: 17027913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of systemic follistatin as an adjuvant to stimulate muscle repair and improve motor function in Pompe mice.
    Foley JW; Bercury SD; Finn P; Cheng SH; Scheule RK; Ziegler RJ
    Mol Ther; 2010 Sep; 18(9):1584-91. PubMed ID: 20551907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skeletal muscle effects of antisense oligonucleotides targeting glycogen synthase 1 in a mouse model of Pompe disease.
    Weiss L; Carrer M; Shmara A; Cheng C; Yin H; Ta L; Boock V; Fazeli Y; Chang M; Paguio M; Lee J; Yu H; Martin A; Raben N; Weiss J; Grossman T; Jafar-Nejad P; Kimonis V
    bioRxiv; 2024 Mar; ():. PubMed ID: 38464319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model.
    Xu F; Ding E; Liao SX; Migone F; Dai J; Schneider A; Serra D; Chen YT; Amalfitano A
    Gene Ther; 2004 Nov; 11(21):1590-8. PubMed ID: 15356673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.